Cargando…
Targeting SIRPα in cancer
Strategies to harness the patient’s immune system to fight cancer have mainly involved adoptive T-cell transfer. We and others have recently highlighted an alternative immunotherapeutic approach to cancer that consists of enhancing the macrophage-mediated clearance of leukemia cells through the bloc...
Autores principales: | Ho, Jenny M., Danska, Jayne S., Wang, Jean C.Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601179/ https://www.ncbi.nlm.nih.gov/pubmed/23525504 http://dx.doi.org/10.4161/onci.23081 |
Ejemplares similares
-
Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants
por: Weiskopf, Kipp, et al.
Publicado: (2013) -
Bad to the bone: B cell acute lymphoblastic leukemia cells mediate bone destruction
por: Rajakumar, Sujeetha A., et al.
Publicado: (2020) -
SIRPαFc treatment targets human acute myeloid leukemia stem cells
por: Galkin, Oleksandr, et al.
Publicado: (2020) -
Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts
por: Theocharides, Alexandre P.A., et al.
Publicado: (2012) -
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells
por: Nuvolone, Mario, et al.
Publicado: (2013)